Content about Watson

November 19, 2012

The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

The year 2012 is coming to an end, and it's been a big year for generic drugs. It's the year that the most lucrative drug of all time became commoditized. It's the year that Watson bought Actavis for $5.6 billion. And it's the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

 

May 28, 2013

Pharmacy Intelligence applies application-based data analytics, computer-animated graphic process simulation and Lean Six Sigma principles to enable a new level of more advanced modeling and forecasting.

Like drinking from a fire hose. That’s one way some pharmacy retailers might describe their efforts to manage the flood of data unleashed every day by their prescription dispensing operations. The goal: to turn that data flow into actionable information they can use to better manage pharmacy workflow and staff resources, boost profitability, reduce customer wait times and make more informed decisions about the capital every retail pharmacy must allocate to technology and staffing.

January 9, 2013

Generic drug maker Watson Pharmaceuticals has hired a former executive from the Generic Pharmaceutical Association to head lobbying at the federal and state level, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals has hired a former executive from the Generic Pharmaceutical Association to head lobbying at the federal and state level, the company said Wednesday.

Watson announced the appointment of James Fenton as VP U.S. government affairs. In the new position, Fenton will work out of Watson's Washington offices and will be responsible for leading the company's expanded federal and state government affairs activities.

November 13, 2012

Towers Watson on Tuesday announced that it has selected Loblaw Companies as the preferred pharmacy services provider for its Towers Watson Canadian Rx Coalition, a collaborative network of private sector drug plan sponsors.

TORONTO — Towers Watson on Tuesday announced that it has selected Loblaw Companies as the preferred pharmacy services provider for its Towers Watson Canadian Rx Coalition, a collaborative network of private sector drug plan sponsors. 

The arrangement with Loblaw is expected to improve employers' ability to offer their employees access to a robust range of drug store health resources and support overall health and wellness needs while enabling long-term sustainability of their benefits programs in the face of rising costs. 

November 1, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

PARSIPPANY, N.J. – Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission earlier this month, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.

 

October 8, 2012

European regulators have approved U.S. drug maker Watson's acquisition of Switzerland-based Actavis, Watson said.

PARSIPPANY, N.J. — European regulators have approved U.S. drug maker Watson's acquisition of Switzerland-based Actavis, Watson said.

Watson said the European Commission had approved its $5.6 billion purchase of the drug maker, formerly based in Iceland, which Watson announced in April 2012.

Watson expects the transaction to be finished by the end of this year, subject to regulatory approval by the Federal Trade Commission. The acquisition is expected to create the world's third-largest generic drug maker.

June 28, 2012

Mylan is challenging the patent protection on a Pfizer drug for treating depression, following an announcement of a similar challenge by Watson made earlier this week.

PITTSBURGH — Mylan is challenging the patent protection on a Pfizer drug for treating depression, following an announcement of a similar challenge by Watson made earlier this week.

Mylan said it had filed for Food and Drug Administration approval of a generic version of Pristiq (desvenlafaxine succinate) extended-release tablets in the 50-mg and 100-mg strengths.

May 16, 2012

Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.

SUPPLIER NEWS — Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion. 


April 26, 2012

Watson has announced its intention to acquire Actavis, the company said.

PARSIPPANY, N.J. — Watson has announced its intention to acquire Actavis, the company said.

Following news reports Tuesday that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced Wednesday that it would buy the latter for $5.6 billion. News media had reported that the deal would be worth $5.9 billion, while there had been estimates in March that Watson would pay up to $7.3 billion.

April 3, 2012

Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

PARSIPPANY, N.J. — Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

Watson announced that it had filed with the Food and Drug Administration for generic versions of Allergan's Lumigan and Latisse (bimatoprost) ophthalmic solution. The products contain the same active ingredient in the 0.01% and 0.03% strengths, respectively, and are used to reduce pressure within the eye in patients with open-angle glaucoma or ocular hypertension.

September 12, 2011

Healthcare giant WellPoint has inked a deal with IBM whereby it will develop applications using IBM's Watson artificial intelligence technology to deliver healthcare information to patients.

INDIANAPOLIS — Healthcare giant WellPoint has inked a deal with IBM whereby it will develop applications using IBM's Watson artificial intelligence technology to deliver healthcare information to patients.

Watson, named for IBM founder Thomas Watson, is a system developed by IBM scientists designed to mimic a human's ability to answer questions posed in natural language that earlier this year appeared on the TV game show "Jeopardy!" and won against two human contestants.

September 12, 2011

At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


At press time, Hurricane Irene was slowly barreling toward the East Coast and threatening the area with a deluge that prompted cities to shut down and had store shelves wiped clean.


March 25, 2011

A generic painkiller made by Watson Pharmaceuticals infringes a patent covering the branded version, a U.S. District Court ruled.

MORRISTOWN, N.J. — A generic painkiller made by Watson Pharmaceuticals infringes a patent covering the branded version, a U.S. District Court ruled.

Watson said Friday that the U.S. District Court for the District of Delaware decided that Watson’s generic version of Cephalon’s Fentora (fentanyl) buccal tablets infringes U.S. Patent No. 6,264,981, though the Food and Drug Administration had approved Watson’s version of the drug.

March 9, 2011

Generic drug maker Watson Pharmaceuticals has promoted two executives to EVP, the company said Wednesday.

MORRISTOWN, N.J. — Generic drug maker Watson Pharmaceuticals has promoted two executives to EVP, the company said Wednesday.

The company gave the promotions to SVP, general counsel and secretary David Buchen and SVP and CFO R. Todd Joyce. Both will continue to report to CEO Paul Bisaro.

May 31, 2010

Columbia Labs is seeking shareholder approval for an agreement in which Watson would acquire the...

March 9, 2010

MORRISTOWN, N.J. Watson Pharmaceuticals and Takeda Pharmaceuticals North America have settled a patent litigation case...

March 8, 2010

Watson Pharmaceuticals has filed a regulatory approval application for a generic version of a painkiller...

January 31, 2010

Watson Pharmaceuticals and HRA Pharma have signed a deal whereby Watson will become the commercial...